- Similar paperwork
- Lawsuit says AZ’s most cancers drug Imjudo infringes patents for blockbuster Yervoy
- BMS also sued previous calendar year in excess of linked drug
(Reuters) – AstraZeneca’s cancer treatment method Imjudo infringes Bristol Myers Squibb Co patents connected to its blockbuster drug Yervoy, Bristol Myers said in a lawsuit produced community Tuesday in Delaware federal court docket.
Bristol Myers alleges that AstraZeneca’s antibody-centered drug fights cancer in the exact way as Yervoy. It is the second U.S. patent lawsuit that Bristol Myers has submitted towards AstraZeneca above most cancers immunotherapies in the previous yr.
A agent for AstraZeneca said the organization was aware of the criticism and will answer to it “at the appropriate time.” Associates for Bristol Myers did not quickly react to a request for remark.
Yervoy, an immunotherapy initial approved by the U.S. Food items and Drug Administration in 2011 to treat melanoma, has also been accepted by the Food and drug administration to treat kidney, lung, colorectal and other forms of most cancers. New York-dependent Bristol Myers sold about $2 billion worthy of of the drug in 2021, according to a organization report.
The Food and drug administration authorised AstraZeneca’s Imjudo last year to address liver and lung most cancers in combination with Imfinzi, a further AstraZeneca cancer drug. Bristol Myers individually sued AstraZeneca for patent infringement final yr in excess of Imfinzi.
In its new lawsuit, Bristol Myers accused AstraZeneca of infringing two patents related to working with antibodies to deal with most cancers and boost a patient’s immune response.
Bristol Myers also reported AstraZeneca knew of the patents or was “willfully blind” to them, arguing it was on see primarily based on licensing conversations and the Imfinzi lawsuit.
The lawsuit seeks an unspecified volume of funds damages.
The scenario is Bristol Myers Squibb Co v. AstraZeneca Prescription drugs LP, U.S. District Court docket for the District of Delaware, No. 1:23-cv-00079.
For BMS: Steven Maslowski, Matthew Pearson, Matthew Hartman and Rachel Elsby of Akin Gump Strauss Hauer & Feld
For AZ: attorney data not readily available
Bristol Myers sues AstraZeneca about cancer-treatment method patents
Our Criteria: The Thomson Reuters Trust Principles.